Abbott Laboratories
ABT
$132.09
$0.090.07%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.11B | 42.34B | 41.95B | 41.22B | 40.73B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.11B | 42.34B | 41.95B | 41.22B | 40.73B |
| Cost of Revenue | 18.98B | 18.73B | 18.73B | 18.26B | 18.17B |
| Gross Profit | 24.13B | 23.62B | 23.22B | 22.95B | 22.55B |
| SG&A Expenses | 11.36B | 11.21B | 11.13B | 10.92B | 10.76B |
| Depreciation & Amortization | 1.78B | 1.83B | 1.88B | 1.89B | 1.92B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.00B | 34.63B | 34.59B | 33.75B | 33.49B |
| Operating Income | 8.11B | 7.72B | 7.36B | 7.47B | 7.24B |
| Income Before Tax | 7.90B | 7.36B | 7.01B | 6.78B | 6.51B |
| Income Tax Expenses | -6.08B | -6.15B | -6.39B | 1.01B | 952.00M |
| Earnings from Continuing Operations | 13.98K | 13.50K | 13.40K | 5.77K | 5.56K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.98B | 13.50B | 13.40B | 5.77B | 5.56B |
| EBIT | 8.11B | 7.72B | 7.36B | 7.47B | 7.24B |
| EBITDA | 11.25B | 10.89B | 10.58B | 10.69B | 10.49B |
| EPS Basic | 7.99 | 7.72 | 7.66 | 3.30 | 3.18 |
| Normalized Basic EPS | 2.80 | 2.65 | 2.52 | 2.57 | 2.47 |
| EPS Diluted | 7.97 | 7.70 | 7.64 | 3.29 | 3.17 |
| Normalized Diluted EPS | 2.79 | 2.64 | 2.51 | 2.56 | 2.46 |
| Average Basic Shares Outstanding | 6.97B | 6.97B | 6.97B | 6.97B | 6.97B |
| Average Diluted Shares Outstanding | 6.99B | 6.99B | 6.99B | 7.00B | 7.00B |
| Dividend Per Share | 2.32 | 2.28 | 2.24 | 2.20 | 2.16 |
| Payout Ratio | 28.42% | 28.92% | 28.62% | 65.30% | 66.47% |